Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Short interest has increased again ,insane actually and they can barely keep the price down.
Oh, this is going to be so much fun soon.
Stock unavailable to short . That is what some are reporting, I think this is also broker dependent but nonetheless great news.
Every large morning buy is a shorted trader in pain, exercised by their broker due to not meeting their margin requirements.
Every cent up TSPT goes it just increases the pressure on the HUGE short count. Can't wait till we blow past $20 IMO
I'm fine with a gradual increase in price, TSPT should be over $12 by the time Q2 financials are out IMO. When those financials are out all bets are off. Under E-trade they have analysis forecast of TSPT loosing 44cents per share on Q2, now I don't know when they will get their royalties from sales but that number is insane. IMO 2012 will be a positive earning year for TSPT, they currently burn through about 15M yearly. If Purdue sells $100M worth of Intermezzo and TSPT gets 20%, Transcept will be positive. Considering sleep aids sell about $2B currently yearly, intermezzo being the only middle of the night drug getting 5% of the market is quite attainable if not easily accomplished. IMO Intermezzo is going to sell like hot cakes. If what people are saying is true that they don't feel lethargic the next morning, Intermezzo is going to become the sleep aid to prescribe.
any upwards movement even if its small just increases the pressure on the large short count. Can't wait to see the numbers up to 4/15
Yes, this stock is a keeper IMO, at least for the near term.
Hold till at least the $20's, I might hold till the 30's if I see the momentum
By the way the short numbers actually increased before March 31, crazy, lol
The runup began after April 1st.
That quick run up to $12.90 was clearly a big short position that bailed, can't wait till the rest do the same.
I'm starting to love this stock...up 10%..go tspt !
$12 just hit, short squeeze has begun, thanks to all who have read my messages
transcept, TSPT , $20's in no time IMO
Intermezzo Rouses Drug Category With $100 Million Push
http://adage.com/article/news/intermezzo-rouses-drug-category-100-million-push/234014
ABC news report on Intermezzo
http://abcnews.go.com/WNT/video/intermezzo-sleeping-pill-fda-approval-low-dose-ambien-health-16075002
Dr. Reena Mehra compares new sleeping pill Intermezzo to other popular pills.
http://abcnews.go.com/Health/video/sleeping-pill-intermezzo-fare-16072680
Dr. Richard Besser discusses the medication designed to treat insomnia.
http://abcnews.go.com/GMA/video/prescription-sleeping-pill-intermezzo-hits-market-16077227?tab=9482931§ion=1206835&playlist=1363742
FOX News - New short-acting sleeping pill available in pharmacies
http://www.foxnews.com/health/2012/04/05/new-short-acting-sleeping-pill-available-in-pharmacies/
Transcept - TSPT
52 week high in the crosshairs, after that its GAME OVER
transcept and intermezzo will be cresting the $20's in no time.
IMO
Intermezzo now on sale , Transcept Pharmaceuticals first product to market.
http://ir.transcept.com/releasedetail.cfm?ReleaseID=662035
it's going for that 10.4 barrier, that can't hold it back much longer
short interest is below 2M for the first time in 7 months, and days to cover has been lowered.
TSPT, transcept has begun its slow creep up, they can't even hold it down when it hits 10.4
shorter, are you going to give up now, or later after having lost more $
Look for TSPT to re-test its next significant overhead resistance levels at $11.40 to $11.88 in the near future.
IMO
Short selling is tricky when there aren’t so many shares "in the float" for individual traders to buy and sell. Imagine a stock that went on a mad tear to more than $70 when they announced they would sell music over the Internet. That stock ’s float at the time would be around 1 million shares. Daytraders bought and sold as fast as they could, driving up the price in leaps and bounds as the Market Makers (who actually execute NASDAQ trades) kept raising the price to encourage sellers and discourage new buyers.
Imagine you shorted the stock at $15 and you saw the price running to $20 then $25 and beyond. What did you do? If you didn’t have a stop loss order in place, you started to panic. You realized you couldn’t withstand a loss much larger than the stock hitting $30 (your broker will insist you deposit more cash in your account to cover the paper loss or force you to cover your short right away – a "short" margin call).
So you called your broker or went online and told the broker to "cover" your position – buy back the stock – at the market price. Problem is, hundreds of other geniuses had the same idea at the same time. Pour that fuel on a fire that daytraders already started and you have LIFTOFF. Everyone is buying at any price they can get. Seventy bucks for a stock that was only $5 a few days before.
Houston, we have a problem.
http://www.tradingstocksguide.com/investing-stocks/short-selling.php
The TSPT squeeze, this is the end of line for many shorters on here
so lets say they have a 10% stop loss, why wouldn't they? Many shorted in the 9.5 to $10 range, come those 11's they will be terminal. It's going to be quite a mess for some.
We knew it was coming, and now its here. Shorts are bailing quickly maybe some 15% have covered and the PPS has crested $10. At least 1.5 million more shares for them to cover, will we see $15 in the near term?
Will we close at HOD, sure seems that way. TSPT on its way to 10.
Transcept Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Conference call scheduled for 4:30 PM Eastern time today
PR NewswirePress Release: Transcept Pharmaceuticals, Inc. – 33 minutes ago
POINT RICHMOND, Calif., March 14, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT - News), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and twelve months ended December 31, 2011.
Transcept reported cash, cash equivalents and marketable securities of $62.4 million at December 31, 2011. Revenue for the quarter ended December 31, 2011 was $12.8 million. This revenue included payments received from Purdue Pharmaceutical Products, L.C., the Transcept U.S. commercialization partner for Intermezzo, for a patent milestone, reimbursement of manufacturing related costs, and an option fee to negotiate for Intermezzo® commercialization rights in Canada and Mexico.
"Purdue plans to launch Intermezzo in early April 2012," stated Glenn A. Oclassen, President and Chief Executive Officer of Transcept. "Purdue has a highly capable and experienced sales and marketing team, and we are confident in their ability to generate significant adoption of Intermezzo. We believe the commercial opportunity is substantial and look forward to reporting Intermezzo royalty revenue in 2012."
Three months ended December 31, 2011 financial results
Transcept recorded $12.8 million of revenue for the quarter ended December 31, 2011 compared to $3.1 million for the quarter ended December 31, 2010. Revenue during the quarter ended December 31, 2011 included a $10 million milestone payment from Purdue for the listing of our formulation patents in the FDA's Orange Book. $2.4 million of other revenue was received from Purdue and included approximately $0.8 million for a non-refundable option to negotiate for the commercialization of Intermezzo in Mexico and Canada and approximately $1.6 million for reimbursement of certain manufacturing-related costs. License fee revenue of $0.4 million related to the final portion of the $25 million up-front non-refundable license fee received from Purdue that was recognized over the estimated period during which Transcept had significant participatory obligations under the collaboration agreement. License fee revenue for the quarter ended December 31, 2010 included $3.1 million for recognition of a portion of the $25 million received from Purdue.
Research and development expense for the quarter ended December 31, 2011 was approximately $3.4 million, compared to approximately $3.0 million for the same period in 2010. Research and development expense included non-cash stock compensation expense of approximately $0.8 million for the quarter ended December 31, 2011 and approximately $0.1 million for the quarter ended December 31, 2010. The increase of approximately $0.7 million was attributable to recording compensation expense related to the vesting of performance-based options upon FDA approval of Intermezzo on November 23, 2011. The increase was partially offset by a decrease of approximately $0.3 million for the Intermezzo development program, principally due to the substantial completion of clinical trials during the fourth quarter of 2010.
General and administrative expense for the quarter ended December 31, 2011 was approximately $4.1 million, compared to approximately $2.7 million for the same period in 2010. General and administrative expense included non-cash stock compensation expense of approximately $1.6 million for the quarter ended December 31, 2011, compared to approximately $0.4 million for the quarter ended December 31, 2010. The increase of approximately $1.2 million was primarily attributable to recording compensation expense related to the vesting of performance-based options upon FDA approval of Intermezzo on November 23, 2011.
Net income for the quarter ended December 31, 2011 was approximately $5.3 million, or $0.39 per share (basic) and $0.37 per share (diluted), compared to a net loss of approximately $2.6 million, or $0.20 per share (basic and diluted), for the quarter ended December 31, 2010. The weighted average shares used to calculate basic and diluted net income per share were 13,663,799 and 14,396,542, respectively, for the quarter ended December 31, 2011. The weighted average shares used to calculate basic and diluted net loss per share were 13,441,744 at December 31, 2010. At December 31, 2011, there were 13,904,515 common shares outstanding and 3,032,517 common shares underlying outstanding options and warrants.
During the first two months of 2012, Transcept issued an additional 594,000 options to purchase common shares. Accordingly, as of February 29, 2012, there were 13,913,491 common shares outstanding and 3,612,541 common shares underlying outstanding options and warrants.
Full year 2011 financial results
Revenue for the year ended December 31, 2011 was $19.7 million compared to $12.5 million for the year ended December 31, 2010. $7.3 million and $12.5 million for the years ended December 31, 2011 and 2010, respectively, related to recognition of a portion of the $25 million non-refundable license fee received from Purdue. Transcept recognized the $25 million license fee over the estimated period during which it had significant participatory obligations under the collaboration agreement. As of December 31, 2011, all revenue from this license fee was recognized. Revenue during the year ended December 31, 2011 included a $10 million milestone payment under the collaboration agreement for the listing of our formulation patents in the FDA's Orange Book. Other revenue during the year ended December 31, 2011 of $2.4 million received from Purdue included approximately $0.8 million for a non-refundable option to negotiate for the commercialization of Intermezzo in Mexico and Canada and approximately $1.6 million for reimbursement of certain manufacturing-related costs. There was no similar revenue during 2010.
Research and development expense for the year ended December 31, 2011 was approximately $11.3 million, compared to approximately $10.7 million for the same period in 2010. Expense associated with the Intermezzo development program, decreased by approximately $3.2 million in 2011 as compared to 2010 as preparations for the NDA resubmission were substantially complete by the end of the year in 2010. Expense associated with the TO-2061 development program increased by approximately $2.2 million in 2011 as compared to 2010 as enrollment in the Phase 2 clinical program accelerated. Research and development expense included non-cash stock compensation expense of approximately $1.3 million for the year ended December 31, 2011 and approximately $0.4 million for the year ended December 31, 2010. The increase of approximately $0.9 million was primarily attributable to recording compensation expense related to the vesting of performance-based options upon FDA approval of Intermezzo on November 23, 2011. Research and development expense also included $0.5 million of severance and benefit continuation expense related to the July 2011 reduction in force. There was no similar expense in 2010.
General and administrative expense for the year ended December 31, 2011 was approximately $12.2 million, compared to approximately $11.0 million for the same period in 2010. General and administrative expense included non-cash stock compensation expense of approximately $3.1 million for the year ended December 31, 2011, compared to approximately $1.4 million for the year ended December 31, 2010. Approximately $1.2 million of the total increase to stock compensation expense was associated with performance-based options. As noted above, the Company began recording compensation expense related to the vesting of performance-based options upon FDA approval of Intermezzo on November 23, 2011. The increase in stock-based compensation expense was partially offset by an approximately $0.9 million reduction in market research expense that was completed in 2010 prior to the Intermezzo NDA resubmission in early 2011.
Net loss for the year ended December 31, 2011 was approximately $3.9 million, or $0.29 per share (basic and diluted), compared to a net loss of approximately $9.3 million, or $0.69 per share (basic and diluted), for the year ended December 31, 2010. The weighted average shares used to calculate net loss per share were 13,534,248 and 13,415,573 for the years ended December 31, 2011 and 2010, respectively.
Cash, cash equivalents and marketable securities totaled $62.4 million at December 31, 2011.
Conference call and webcast information
Transcept will host a conference call and webcast on Wednesday, March 14, 2012, at 4:30 p.m. ET to discuss fourth quarter and full year 2011 financial results. Telephone numbers for the live conference call are 877-638-4558 (U.S.) or 914-495-8537 (International). The webcast can be accessed on the Investors page of the Transcept website at www.transcept.com and will be available for replay until close of business on May 31, 2012. A playback of the call will be available through March 19, 2012, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International), replay passcode: 50417502.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com.
Intermezzo will be on sale the beginning of April and that's when the real fun begins, per the latest PR
We are over 9 in after hours after earnings but will shorters, short more tomorrow or will finally give up and cover. They might wait till 10, regardless they are in a very precarious situation. I would want to be the first to cover and not last. Easily over $15 once the shorters run for it. IMO
We are slowly heading up, not in the mid 9's but the short positions are decreasing
Short interest is decreasing, days to cover has increased exponentially
day interest avg volume days to cover
1/31/2012 2,097,626 107,154 19.575807
1/13/2012 2,138,978 125,417 17.054929
12/30/2011 2,101,070 225,588 9.313749
12/15/2011 2,106,697 598,078 3.522445
11/30/2011 2,368,418 721,909 3.280771
Read more: http://www.nasdaq.com/symbol/tspt/short-interest#ixzz1mgYqc700
Outperform at JMP Securities
News Breaks
February 10, 2012
06:16 EDT TSPT
theflyonthewall.com: Transcept Pharmaceuticals initiated with an Outperform at JMP Securities
Target $15. :theflyonthewall.com
News Breaks
February 10, 2012
06:16 EDT TSPT
gotcha, well that person still believes the price will be higher than the strike of 8.09 when it vests
It was a stock option right to buy at 8.09 for 45,000 shares NOT a buy.
http://www.secform4.com/filings/1178711/000118143112005722.htm
Manny
http://quotes.barrons.com/tspt/ownership
Avg Vol (3 month)3: 421,658
Avg Vol (10 day)3: 130,167
Shares Outstanding5: 13.54M
Float: 6.56M
% Held by Insiders1: 41.58%
% Held by Institutions1: 27.80%
Shares Short (as of Dec 30, 2011)3: 2.10M
Short Ratio (as of Dec 30, 2011)3: 5.00
Short % of Float (as of Dec 30, 2011)3: 27.00%
Shares Short (prior month)3: 2.11M
Options expiration week...
what do you expect after 18 green trading days..
Will get in Low $7.... by friday.
320k volume....
shorts day to cover has tripled since Dec. 15th
http://www.nasdaq.com/symbol/tspt/short-interest
Over 8.5 today as i assumed, mid 9's in february, over $10 by April
thats actually very good news for longs, it means the slow but steady increase is due to other long positions. Can't wait till we hit the $10's. I would say no later than April IMO
You still short ? I see you posting on other boards on what's causing the spike...lol..
Short interest still 2.1 mil
As of dec 31st they have covered only 5k shares.......
We are going for a close over $8.50
To all those shorts, it might just be time to find another victim, this one won't be coming down easily.
$10 + by April
Go TSPT
This is great volume for us longs. If it can stay below 50k daily shorters and day traders will have nothing to do here.
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
535
|
Created
|
05/30/07
|
Type
|
Free
|
Moderators |
http://www.novacea.com/
http://finance.yahoo.com/q/h?s=tspt
http://www.form4oracle.com/company?cik=0001178711&ticker=novc
Transcept Pharmaceuticals, Inc. operates as a specialty pharmaceutical company. It focuses on the development and commercialization of proprietary products that address therapeutic needs in the fields of psychiatry and sleep medicine. The company?s lead product includes Intermezzo, which has completed Phase III clinical trials for sleep aid. Transcept Pharmaceuticals is based in Richmond, California.
Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate includes Asentar, which is in Phase III clinical trials for the treatment of androgen-independent prostate cancer; and AQ4N, which is in Phase 1/2 clinical trial for the treatment of glioblastoma multiforme. The company has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and Pierre Fabre Medicament. The company, formerly known as D-Novo Therapeutics, Inc., was founded in 2001. Novacea is headquartered in South San Francisco, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |